AIM
CNCE

Alambic Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Alambic Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,934
Closed -$196K – 54
2020
Q3 		$196K Buy
19,934
+2,034
+11% +$20K 2.15% 15
2020
Q2 		$178K Hold
17,900
– – 0.45% 106
2020
Q1 		$158K Sell
17,900
-3,416
-16% -$33.7K 0.38% 102
2019
Q4 		$197K Buy
+21,316
New +$151K 0.16% 208

Other funds holding CNCE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alambic Investment Management's CNCE Position: Q4 2020 in Review

Alambic Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2020, closing a stake of 19,934 shares — an estimated $196K sold.

Alambic Investment Management first reported a position in CNCE in Q4 2019 and held it in 4 quarters. The position peaked at $197K in Q4 2019. 100 funds tracked by Wall St. Rank hold CNCE as of Q4 2020.

  • Alambic Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 19,934 Concert Pharmaceuticals, Inc. shares in Q4 2020, an estimated $196K.
  • Alambic Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2019 and held it in 4 quarters.
  • Alambic Investment Management's Concert Pharmaceuticals, Inc. position peaked at $197K in Q4 2019.
  • 100 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.